V itamin D deficiency has been known for a long time to cause skeletal diseases such as rickets in children, and osteomalacia in adults. 1 Apart from its importance in the management of osteoporosis, lately it was recognized that an association exists between vitamin D deficiency and many acute and chronic illnesses such as cancer, type 1 and type 2 diabetes mellitus, hypertension, cardiovascular diseases, infectious diseases, autoimmune diseases, and depression. [2] [3] [4] [5] [6] [7] With the improved understanding of the risks of vitamin D deficiency, more attention for the evaluation of vitamin D status has been undertaken and the clinical demand for assessment of vitamin D status has rapidly increased. In general, measurement of 25-hydroxyvitamin D (25-OHD) level in serum or plasma is accepted as a reliable indicator of vitamin D status, but assay technology needs to be able to measure both D 2 and D 3 metabolites. Thresholds of serum 25-OHD concentration to define vitamin D deficiency are highly debated, but there is a consensus agreement that vitamin D sufficiency should be defined as 25-OHD level of >75 nmol/L (>30ng/ml), insufficiency as 50-75 nmol/L (20-30 ng/ml), and deficiency as <50 nmol/L (<20 ng/ml). 8 These deficiencies are widespread and it is higher in the elderly and hospitalized population. 9, 10 Studies from Saudi Arabia revealed a varying prevalence of vitamin D deficiency (50-100%) in all age groups. [11] [12] [13] [14] This high variability of prevalence in the same ethnic group raises the questions of reliability and accuracy of the 25-OHD assays used. With the recognized epidemic of hypovitaminosis D worldwide, it became imperative to accurately assess circulating levels of 25-OHD. However, the issue of substantial variability among different assays make clinical assessment of the vitamin D status of an individual patient problematic. 15, 16 Binkley et al 17 reported that it is less appreciated that the assays, which are used to measure levels of 25-OHD may yield discrepant results, and they were the first to drew attention of the clinical community to the large variability in 25-OHD results both between methods and between laboratories. Several assays are being used for the measurement of vitamin D in serum or plasma including competitive binding assay, different manual and automated immunoassays, high-performance liquid chromatography (HPLC), and the lately developed liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay, which was found to be the most accurate and is currently considered the gold standard method for the assessment of 25OHD level. 18, 19 King Fahd Hospital of the University, Al-Khobar, Saudi Arabia laboratory uses the chemiluminescence immunoassay (CLIA) method to assess levels of 25-OHD, and we hypothesized that such an assay is overestimating the prevalence of hypovitaminosis D. The objective of this study is to compare the performance of the CLIA assay method used at our hospital with the radio-immuno assay (RIA) and the LCMS/MS assay methods among a sample of the Saudi population.
Methods. This cross-sectional study was carried out between January 2011 and December 2012 using a convenient available sample. Special Clinical Chemistry at King Fahd Hospital of the University, Al-Khobar using DiaSorin (Liaison®, Saluggia, Italy) analyzer. During the first incubation, 25-OHD was dissociated from the binding protein and was binded to the specific antibody on the solid phase. At the end of 10 minutes, vitamin D that linked to the tracer was added and incubated for another 10 minutes. The unbound tracer was washed and the starter reagents were added to initiate the chemiluminescence reaction. The light signal was measured by photomultiplier as relative light units (RLU) and was inversely proportional to the concentration of 25OHD present in calibrator control, or study sample. Chemiluminescence immunoassay is a direct competitive CIA for quantitative determination of total 25-OHD in serum. It is a popular assay method and accounted for 36% of the sample returned during the year 2009 carried out by the External Quality Assessment Scheme for vitamin D metabolites (DEQAS). 20 The sample analysis during the year 2012 carried out by the DEQAS revealed run-to-run coefficients of variation (CVs) in the range of 9.6-13.7%.
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Radio-immuno assay. Plasma samples were analyzed using Gamma-B, 25-hydroxyvitamin D RIA (IDS, Boldon, UK) according to the manufacturer's instructions. Briefly, after following centrifugation a proportion of the supernatant were incubated with 125 Ilabelled 25-OHD tracer and sheep antibody to 25-OHD. Antibody-bound 125 I-labelled 25-OHD was separated using antisheep IgG cellulose followed by centrifugation and decanting. Concentration of 25-OHD is inversely proportional to the bound radioactivity. To establish analytic quality standards, controls and samples were analyzed in duplicate and any sample with a coefficient of variation of >10% were reanalyzed for confirmation. The control samples provided by the manufacturer were within the recommended range. The intra-assay precision was <7% and the inter-assay precision was <9% with sensitivity of -3 nmol/L.
Liquid chromatography-tandem mass spectrometry. The third method used to measure 25-OHD levels in this study was LC-MS/MS, which was carried out at the Quest Diagnostics, Lab One, Ohio, USA using an API 3000 triple-quadrupole mass spectrometer (Applied Biosystems/MDS Sciex, AB Framingham, MA, USA) following the guidelines by the US National Institute of Standards and Technology (NIST). Sample analysis was performed according to the manufacturer's instructions. Briefly, initial extraction was carried out via protein precipitation followed by separation using the HPLC method, then, detection and quantification was carried out via tandem mass spectrometry. Concentration of both 25-OHD 3 and 25-OHD 2 were used to calculate the total 25-OHD levels. Analytical sensitivity was 4ng/ml and the reportable range for total 25-OHD was 4-1024ng/ml.
Statistical analysis. Regression analysis and BlandAltman plots were used for comparison between assays. Bland-Altman plots were also used to identify mean bias and the 95% limits of agreement between assays. Vitamin D level was classified as follows: vitamin D sufficiency defined as 25OHD level of ≥75 nmol/L (≥30ng/mL), insufficiency as 50-75nmol/L (20-30ng/mL), and deficiency as ≤50nmol/L (≤20ng/mL). Statistical analysis was performed using the Statistical Package for Social Sciences software, version 14.0 (SPSS Inc, Chicago, IL, USA). Data was presented as a mean±standard deviation (SD). The mean serum 25-OHD values with 95% confidence intervals (CI) for each assay results were calculated, and a p-value of <0.05 was considered as significant.
Results. A total of 200 participants with an average age of 45.7±16.1 years, consisting of 50 males (48.1±17.1 years) and 150 females (44.8±15.7 years) were included. Baseline demographic data of the participants with the mean and ranges of their different variables is given in Table 1 . The findings revealed a low inter-assay agreement regarding the level of 25-OHD (Figure 1) There were also considerable differences between the 3 methods in proportion of participants classified as having low vitamin D. Using a 30mg/mL as a cut-off value for normal 25OHD, 6% were found to have normal levels using CLIA, 9% using RIA, and 22% using LCMS/ MS. Analysis also showed that 57.3% of subjects had Table 2 ). The estimated parameters were negative and there were no statistically significant differences found, which indicates that the difference in variation between the methods were higher while the serum 25OHD level decreases ( Table 2 ). The correlation of CLIA with LC-MS/MS was low (R 2 =0.53), which is much lower than the correlation between RIA and CLIA -chemiluminescence immunoassay, RIA -radio-immuno assay, LC-MS/MS -liquid chromatography-tandem mass spectrometry, HPLC -high-pressure liquid chromatography =0.87). The correlation between CLIA and RIA is also very low (R 2 =0.46). The assay bias was evaluated using Bland-Altman plots (Figures 2-4) . The formula used to calculate the 95% CI was CI=mean ±1.96 SD. Figure 2 shows the bias between CLIA and RIA. The mean bias for CLIA-RIA is +20.2 with upper limit of 57.0 and lower limit of -16.7. The mean value lies between the upper and lower limit. The bias between CLIA and LCMS/MS is shown in Figure 3 . The mean bias for CLIA-LCMS/MS was +27.7 with upper limit of 68.5 and lower limit of -13.0. The mean value lies between the upper and lower limit, while the bias between RIA and LCMS/MS is shown in Figure 4 . The mean bias for RIA-LCMS/MS was +24.2 and the upper limit was 53.5 and the lower limit was -5.1.
Discussion. As a result of increased interest in the role of vitamin D in general health, the use of vitamin D testing has grown in recent years. Several assays have been developed for the measurement of vitamin D, and laboratories have started to use quick, easy, less time consuming, and less accurate automated assays instead of the more accurate but labor intensive methodology. Evaluation of the recently established automated assays showed variability of performance with wider CVs, inaccuracy of the results, failure to achieve minimal performance goals, poor cross-reactivity with 25-OHD 2 , and interference from heterophilic antibodies. 21 This raised concerns regarding reliability of the reported results and the validity of inter-laboratory comparisons. 20, 22 DiaSorin (LIAISON®) vitamin D assay an automated CLIA methodology is the most commonly used commercial platform among laboratories participating in the DEQAS. 23 The manufacturer's kit insert suggests a recovery of 100% for 25-OHD 3 and 75% for 25-OHD 2 ; however, DEQAS reported in 2005 a recovery of 54.2% for 25-OHD 3 and 29.1% for 25-OHD 2 . 24 The CLIA is also the only method used by most of the laboratories in Saudi Arabia, and it is the highest when using the LC-MS/MS assay method and the number of subjects diagnosed with vitamin D deficiency by CLIA method was higher than the number of subjects diagnosed by LC-MS/MS (80.8% versus 57.3%), which indicates that the CLIA method clearly overestimates the number of individuals with 25-OHD concentration <50nmol/L (<20ng/ml) as compared with the LC-MS/MS assay method. The LC-MS/MS is currently considered the best method for evaluation of 25-OHD levels because to the extract procedure ensures that both free and protein bound 25-OHD are quantified, and it can separate and accurately quantitate both 25-OHD 2 and 25-OHD 3 . 25 Several studies used the LC-MS/MS as the gold standard method during evaluation of other assay procedures. [26] [27] [28] However, the instrument is expensive and the systems require specialized expertise.
The precision for CLIA assay was reported by Harrison et al 29 to be consistently poor. Moon et al 27 found that the number of subjects with 25-OHD concentration <50 nmol/L by LC-MS/MS was 44.6% compared with 52.2% by CLIA (LIAISON®). Snellman et al 29 on reported 204 twins, and found that 8% of the subjects were insufficient using HPLC-APCI-MS, 22% by RIA and 43% by CLIA. While, Lai et al 30 studied 813 patients used DiaSorin (LIAISON®) analyzer for CLIA at 2 different laboratories (laboratories A and B) and found that 46% (355/765) were classified as vitamin D deficient using CLIA compared with 17% (128/765) using LC-MS/MS at laboratory A, and 36% (76/209) versus 20% (41/209) for laboratory B indicating that one in 3 patients who were tested were misclassified by CLIA methodology as having deficiency of vitamin D. Their findings also indicated that the variability in vitamin D level is existing not only between assays, also between laboratories. Within assay and between assay variability in measurements of 25-OHD levels were also reported by previous studies. 31, 32 Linear regression analysis from this study revealed that parameters estimates are negative and highly statistically significantly different from zero, which indicates that the difference in variation between the methods were higher as the serum 25-OHD level decreases, and as most of our patients had low 25OHD levels, the variations is exaggerated. Contrary to our findings, Snellman et al 29 found the parameters estimate to be positive, and in their study the difference in variation between the methods were higher as the serum 25OHD levels increase. We also found poor correlation between CLIA and both RIA (R 2 =0.46) and LC-MS/MS (R 2 =0.53) and, which is different from the finding of other studies 27 found negative bias of -13.5% when they compared CLIA with LC-MS/MS. The presence of bias may justify assay specific decision limits and calls for the standardization of the methods used to assess vitamin D and its metabolites. 21, 32, 33 We recommend the standardization of assays should also be implemented in Saudi Arabia.
Our findings suggest that commonly used immunoassays for evaluation of vitamin D status can lead to under-estimation of vitamin D level with overdiagnosing of hypovitaminosis D. The high reported prevalence of vitamin D deficiency in our community is possibly related to the use of such imprecise assays. This implies that some of the patients may be treated inappropriately as the treatment decisions are likely to be influenced substantially by the 25-OHD assay being used.
There are several implications that arise from this study and cannot be ignored. It appears that the assays used to diagnose vitamin D levels, in most if not all over the country, is incorrect and based on these results patients are treated. Due to this fact we urge the medical fraternity to conduct similar studies to ours and make recommendations to appropriate authorities to streamline the diagnostic procedures for vitamin D assessment.
The strength of this study arises from the fact that we compared the commonly used immunoassays with the gold standard method in Saudi Arabia where the prevalence of vitamin D deficiency was reported to be high. However, our study has some limitations including the small sample size, being non-randomized and hospital based, in addition to the fact that not all assays were carried out at a local laboratory.
In conclusion, recently there has been increased interest in the relevance for vitamin D to human heath accompanied by increase demand of vitamin D testing that has led to the use of less precise assays. We found a large variation between the results of the 3 studied assays and the use of CLIA led to underestimation of the vitamin D level and overestimation of the number of subjects with low vitamin D level. We recommend the use of the gold standard LC-MS/MS assay, and we call for a large national community based study of the prevalence of low vitamin D using the gold standard method.
